Amedra announced the relaunch of Adrenaclick (epinephrine) auto-injector for the emergency treatment of life-threatening allergic reactions in patients who are at risk for or have a history of anaphylaxis. These reactions include anaphylaxis to stinging and biting insects, allergy injections, food, medicines, exercise, or unknown causes.
Epinephrine acts on both alpha and beta-adrenergic receptors. Through its action on alpha-adrenergic receptors, epinephrine decreases the vasodilation and increased vascular permeability that occurs during anaphylaxis, which can lead to loss of intravascular fluid volume and hypotension. Through its action on beta-adrenergic receptors, epinephrine causes bronchial smooth muscle relaxation and helps alleviate bronchospasm, wheezing and dyspnea that may occur during anaphylaxis.
Adrenaclick had been manufactured by Shionogi’s subsidiary, Sciele Pharma. Shionogi announced the discontinuation of Adrenaclick effective March 30, 2012.
Adrenaclick is available as a single-dose auto-injector in 0.15mg and 0.3mg strengths as 2-pack cartons.
For more information call (888) 894-6528 or visit AmedraPharma.com.